XML 55 R43.htm IDEA: XBRL DOCUMENT
v3.25.1

Related Party Transactions - Collaboration and License Agreements (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 20, 2023 | Dec. 31, 2023 | Mar. 31, 2025 | Mar. 31, 2024 | Dec. 31, 2024
Related Party Transaction [Line Items] |  |  |  |  |
Common stock, shares issued |  |  | 79,418,438 |  | 78,397,380
Offering costs |  |  | $ 12 | $ 635 |
Shares issued to related party |  |  | 79,418,438 |  | 78,397,380
Service revenue - related party |  |  | $ 1,926 | 697 | $ 697
Asset purchase agreement funding included in contract price of license agreement |  | $ 5,800 |  |  |
Gain on sale of nonfinancial assets |  |  |  | 29,018 |
Janssen Pharmaceuticals Inc | Asset Purchase Agreement |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |
Service revenue - related party |  |  | 1,900 |  |
Deferred revenue recognized as service revenue during the period |  |  | 741 | 700 |
Initial agreement term | 4 years |  |  |  |
Written days-notice to terminate agreement | 90 days |  |  |  |
Milestone funding |  |  | 60,000 |  |
Non-refundable upfront cash funding |  | 65,000 |  |  |
Milestone funding for extension of RPGR product clinical trials |  |  | 50,000 | 50,000 |
Milestone funding for development of drug substances |  | 10,000 |  |  |
Milestone funding for development of drug products |  | 5,000 |  |  |
Milestone funding for sale of drug products in the US |  | 175,000 |  |  |
Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy |  | 75,000 |  |  |
Milestone funding for transfer of manufacturing technology |  | 25,000 |  |  |
Milestone funding upon regulatory approval |  | 10,000 |  |  |
Deferred revenue - related party included in contract price of license agreement |  | 30,600 |  |  |
Variable consideration for services included in contract price of license agreement |  | 1,800 |  |  |
Contract price of license agreement |  | 92,300 |  |  |
Offsetting credit for transition services |  | 5,100 |  |  |
Performance obligation for process performance qualification services |  | 2,900 |  |  |
Performance obligation for commercial supply of RPGR product |  | 6,900 |  |  |
Performance obligation for manufacturing technology transfer |  | 28,700 |  |  |
Performance obligation for sale of nonfinancial assets |  | 53,800 |  |  |
Milestone funding allocated to process performance qualification services |  |  | $ 10,000 | 1,600 |
Milestone funding allocated to commercial supply of RPGR product |  |  |  | 3,800 |
Milestone funding allocated to manufacturing technology transfer |  |  |  | 15,600 |
Milestone funding allocated to sale of nonfinancial assets |  |  |  | $ 29,000 |
Janssen Pharmaceuticals Inc | Asset Purchase Agreement | Maximum |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |
Contingent Funding Available |  | $ 350,000 |  |  |

X
- Definition Days of written notice needed in order to terminate the asset purchase agreement. + References No definition available. + Details
Name: | mgtx_AgreementTerminationPeriodDaysWrittenNotice
Namespace Prefix: | mgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_AssetPurchaseAgreementFundingReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement. + References No definition available. + Details
Name: | mgtx_AssetPurchaseAgreementFundingReclassified
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_ContingentFundingAvailable
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total contract price of license agreement. + References No definition available. + Details
Name: | mgtx_ContractPriceOfLicenseAgreement
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References No definition available. + Details
Name: | mgtx_DeferredRevenueRecognizedDuringPeriod
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) on the sale of non-financial assets. + References No definition available. + Details
Name: | mgtx_GainLossOnSaleOfNonfinancialAssets
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial duration period of the asset purchase agreement. + References No definition available. + Details
Name: | mgtx_InitialAgreementPeriodDuration
Namespace Prefix: | mgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone funding received and allocated to performance obligation for commercial supply of RPGR product. + References No definition available. + Details
Name: | mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received and allocated to performance obligation for manufacturing technology transfer. + References No definition available. + Details
Name: | mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services. + References No definition available. + Details
Name: | mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received and allocated to performance obligation for sale of nonfinancial assets. + References No definition available. + Details
Name: | mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForDevelopmentOfDrugProducts
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForDevelopmentOfDrugSubstances
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForExtensionOfClinicalTrials
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForRegulatoryApproval
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingForTransferOfManufacturingTechnology
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_MilestoneFundingReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Offsetting credit for transition services in determining contract price under license agreement. + References No definition available. + Details
Name: | mgtx_OffsettingCreditForTransitionServices
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement contract price allocated to performance obligation for commercial supply of RPGR product. + References No definition available. + Details
Name: | mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement contract price allocated to performance obligation for manufacturing technology transfer. + References No definition available. + Details
Name: | mgtx_PerformanceObligationForManufacturingTechnologyTransfer
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services. + References No definition available. + Details
Name: | mgtx_PerformanceObligationForProcessPerformanceQualificationServices
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement contract price allocated to performance obligation for sale of nonfinancial assets. + References No definition available. + Details
Name: | mgtx_PerformanceObligationForSaleOfNonfinancialAssets
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Related-party deferred revenue reclassified under provisions of new license agreement. + References No definition available. + Details
Name: | mgtx_RelatedPartyDeferredRevenueReclassified
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References No definition available. + Details
Name: | mgtx_ServiceRevenueFromRelatedParties
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Variable consideration included in provisions of new license agreement. + References No definition available. + Details
Name: | mgtx_VariableConsiderationForServices
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |